<DOC>
	<DOCNO>NCT00125151</DOCNO>
	<brief_summary>A multicentre study investigate pharmacokinetics , clinical efficacy safety nanofiltered Cetor® ( call C1-esteraseremmer-N development phase ) treatment hereditary angioedema ( HAE ) perform . This study ( KB2003.01 ) consist three part : Part A - pharmacokinetics ( phase II ) ; Part B - treatment attack angioedema ( phase III ) ; Part C - prophylactic use C1 inhibitor ( phase III ) . Parts B + C provide data efficacy C1-esteraseremmer-N . The change within manufacture process C1-esteraseremmer-N , compare Cetor® nanofiltration omission hepatitis B immunoglobulin , likely affect tolerability . The nanofiltration provide safety regard virus . In Part B study , 15 attack hereditary angioedema treat open-label C1-esteraseremmer-N . Attack severity duration monitor subjective experience patient ( show sensitive way monitor attack severity ) compare historical ( literature ) data . If possible , attack acquire angioedema also include .</brief_summary>
	<brief_title>C1-Esteraseremmer-N Treatment Hereditary ( Acquired ) Angioedema</brief_title>
	<detailed_description>A multicentre study investigate pharmacokinetics , clinical efficacy safety nanofiltered Cetor® ( call C1-esteraseremmer-N development phase ) treatment hereditary angioedema ( HAE ) perform . This study ( KB2003.01 ) consist three part : Part A - pharmacokinetics ( phase II ) ; Part B - treatment attack angioedema ( phase III ) ; Part C - prophylactic use C1 inhibitor ( phase III ) . Parts B + C provide data efficacy C1-esteraseremmer-N . The change within manufacture process C1-esteraseremmer-N , compare Cetor® nanofiltration omission hepatitis B immunoglobulin , likely affect tolerability . The nanofiltration provide safety regard virus . In Part B study , 15 attack hereditary angioedema treat open-label C1-esteraseremmer-N . Attack severity duration monitor subjective experience patient ( show sensitive way monitor attack severity ) compare historical ( literature ) data . If possible , attack acquire angioedema also include .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>Inclusion criterion HAE type I type II patient : Established diagnosis hereditary angioedema ( type I II ) : markedly decrease C1 inhibitor activity ; decrease ( type I ) , normal elevate ( type II ) level C1 inhibitor antigen ; decrease level C4 . Age ≥ 16 year Evidence peripheral , abdominal , facial , laryngeal genitourinary attack angioedema moderate severe intensity , start less 5 hour infusion . An attack define moderate affect normal daily activity patient way . Severe attack define inability perform normal daily activity . Signed informed consent patient patient 's legal representative 18 year old Inclusion criterion acquire angioedema patient : Established diagnosis acquire angioedema : recurrent attack angioedema without urticaria ; family history ; decrease functional C1 inhibitor ; decrease level C4 . Autoantibodies C1 inhibitor decrease C1q onset third decade life . Age ≥ 16 year Evidence peripheral , abdominal , facial , laryngeal genitourinary attack angioedema moderate severe intensity , start less 5 hour infusion . An attack define moderate affect normal daily activity patient way . Severe attack define inability perform normal daily activity . Currently treat C1 inhibitor concentrate reverse angioedema . Signed informed consent patient patient 's legal representative 18 year old Exclusion criterion HAE type I type II patient : Presence clinicallyrelevant antiC1 inhibitor autoantibody Participation another pharmaceutical clinical study , interfere study , last 3 month prior study , Part A protocol . Addiction narcotic/pain medication case abdominal attack Bcell malignancy Use narcotic medication within 3 day prior attack . Use heparin within last two day prior study Pregnancy lactation History allergic reaction C1 inhibitor concentrate blood product Exclusion criterion acquire angioedema patient : Participation another pharmaceutical clinical study , interfere study , last 3 month prior study Addiction narcotic/pain medication case abdominal attack Use narcotic medication within 3 day prior attack . Use heparin within last two day prior study Pregnancy lactation . History allergic reaction C1 inhibitor concentrate blood product</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>MeSH : angioneurotic edema , complement 1 inactivators</keyword>
	<keyword>Hereditary angioedema type I II , Acquired angioedema</keyword>
</DOC>